Esophagitis Clinical Trial
Official title:
Placebo Controlled, Confirmatory Clinical Investigation in Patients With Gastro-oesophageal Reflux, to Characterise the Acid Neutralisation Activity of a Calcite Chewing Gum, Using Oesophageal Ambulatory pH Monitoring
NCT number | NCT05129670 |
Other study ID # | 5032701 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 1, 2022 |
Est. completion date | May 22, 2023 |
Verified date | October 2022 |
Source | Reckitt Benckiser Healthcare (UK) Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This investigation is designed to evaluate the acid neutralisation action of a new test product versus unmatched placebo.
Status | Completed |
Enrollment | 27 |
Est. completion date | May 22, 2023 |
Est. primary completion date | May 22, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Patient with a primary diagnosis of symptomatic GORD in accordance with the Montreal definition. Patients must have experienced frequent troublesome heartburn and / or regurgitation (with or without dyspepsia symptoms) of mild/moderate intensity. If the patient also has other symptoms, the heartburn, regurgitation or dyspepsia should be the predominant symptoms. 2. Patient that are healthy (with the exception of a diagnosis of GORD) as determined by past medical history and vital signs at screening. Exclusion Criteria: 1. Patients with a history or active gastrointestinal disease (gastroduodenal ulcer, gastrointestinal haemorrhage, mechanical obstruction or perforation) or hiatus hernia which is greater than 3 cm or a history of conditions that can lead to abnormal oesophageal pH. 2. Patients experiencing frequent troublesome heartburn and / or regurgitation (with or without dyspepsia symptoms) of severe intensity 3. Patients who are unwilling to refrain from using antacids or alginates 24 hours prior to the start of the treatment visit. 4. Patients who are unwilling to refrain from using proton pump inhibitors (PPIs), H2 antagonists, motility stimulants or other medicines for relief of symptoms of acid reflux disease 2 weeks prior to the start of treatment period. |
Country | Name | City | State |
---|---|---|---|
Ireland | Mercy University Hospital | Cork | County Cork |
Lead Sponsor | Collaborator |
---|---|
Reckitt Benckiser Healthcare (UK) Limited |
Ireland,
DeMeester TR, Wang CI, Wernly JA, Pellegrini CA, Little AG, Klementschitsch P, Bermudez G, Johnson LF, Skinner DB. Technique, indications, and clinical use of 24 hour esophageal pH monitoring. J Thorac Cardiovasc Surg. 1980 May;79(5):656-70. — View Citation
Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med. 1999 Apr 12;159(7):649-57. doi: 10.1001/archinte.159.7.649. — View Citation
Vandenplas Y, Hassall E. Mechanisms of gastroesophageal reflux and gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2002 Aug;35(2):119-36. doi: 10.1097/00005176-200208000-00005. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To measure efficacy of the calcite chewing gum versus unmatched placebo by measurement of the mean percentage of time (%) that the pH of the oesophagus is greater or equal to 4 up to 1 hour post dosing | The mean percentage of time (%) that pH is greater or equal to 4 within the oesophagus during the 0-1 hour post dose monitoring period. | 0 to 1 hour post dose | |
Secondary | To evaluate the efficacy of the test product versus the unmatched placebo by measurement of the time (mins) taken to observe the first non-acidic reflux event (pH greater or equal to 4 throughout event) immediately after the start of dosing | Time (mins) to first non-acidic reflux event (pH greater or equal to 4 throughout event) | 0 to 2 hours post dose | |
Secondary | To evaluate the efficacy of the test product versus the unmatched placebo by recording the number of acid reflux events (pH is below pH 4) for up to 2 hours post dose | The number of acid reflux events (pH is below pH 4) for up to 2 hours post dose | 0 to 2 hours post dose | |
Secondary | To evaluate the efficacy of the test product versus the unmatched placebo by recording the total number of reflux events up to 2 hours post dose | The total number of reflux events for up to 2 hours post dose | 0 to 2 hours post dose | |
Secondary | To evaluate the efficacy of the test product versus the unmatched placebo by recording the mean percentage of time (%) that the pH within the oesophagus is raised greater or equal to 4 over the period 1-2 hour post dose | The mean percentage of time (%) that pH is greater or equal to 4 within the oesophagus during the 1-2 hour post dose monitoring period. | 1 to 2 hours post dose | |
Secondary | To evaluate the efficacy of the test product versus the unmatched placebo by recording the mean percentage of time (%) that the pH within the oesophagus is raised greater or equal to 4 over the period 0-2 hour post dose | The mean percentage of time (%) that pH is greater or equal to 4 within the oesophagus during the 0-2 hour post dose monitoring period. | 0 to 2 hours post dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00272818 -
Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
|
||
Recruiting |
NCT05326113 -
The Effect of Physiotherapy on Post POEM Reflux
|
N/A | |
Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
Terminated |
NCT02575391 -
The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00123630 -
A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
|
Phase 2 | |
Completed |
NCT00256529 -
Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia
|
N/A | |
Completed |
NCT00081315 -
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00471094 -
Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis
|
Phase 2 | |
Completed |
NCT00579410 -
Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule
|
N/A | |
Recruiting |
NCT05109819 -
Esophagus-sparing Radiotherapy for Metastatic Spinal Cord Compression.
|
N/A | |
Withdrawn |
NCT01824199 -
CYP2C19 Genotype Predictor of Gastric Acid Suppression
|
Early Phase 1 | |
Completed |
NCT01556919 -
Esophageal Monitoring Device for Assessing Mucosal Impedance
|
||
Active, not recruiting |
NCT03835663 -
The Bacterial Composition of the Stomach in Reflux Disease
|
||
Completed |
NCT00195208 -
Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis
|
Phase 3 | |
Completed |
NCT00175045 -
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
|
Phase 2 | |
Recruiting |
NCT05004155 -
Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population
|
||
Completed |
NCT03228147 -
Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment
|
N/A | |
Completed |
NCT00133770 -
Intravenous (IV) Pantoprazole in Erosive Esophagitis
|
Phase 4 | |
Completed |
NCT01322633 -
Risk of Cancer Among Pantoprazole Users
|
N/A |